Holen Sie sich die Stockscreener-App
94.86
1.12%
-1.07
Handel nachbörslich:
94.84
-0.02
-0.02%
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY - MarketBeat
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY - marketbeat.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp - Barchart.com
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openPR.com
Incyte reports strong 54-week data from late-stage skin disorder study - MSN
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte Corp (INCY) board rep logs 421-share RSU fee grant - Stock Titan
Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees - Stock Titan
Incyte (INCY) director takes 265-share board fee in stock - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Yahoo Finance
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
Citizens reiterates Incyte stock rating on pipeline progress By Investing.com - Investing.com UK
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - marketbeat.com
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corporation (INCY) Announces Board Member Resignation - GuruFocus
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView
Incyte (INCY) Board member Susanne Schaffert to step down April 15, 2026 - Stock Titan
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - Yahoo Finance
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
(INCY.O) | Stock Price & Latest News - Reuters
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC - MarketBeat
Fairvoy Private Wealth Boosts Incyte Corporation Holdings - National Today
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Vanguard disaggregates holdings; reports 0% in Incyte (INCY) - Stock Titan
Incyte Corporation (INCY) Announces Executive Leadership Title C - GuruFocus
Incyte Announces Key Executive Leadership Changes and Integration of U.S. Commercial Teams for Long-Term Growth - minichart.com.sg
INCYTE (NASDAQ: INCY) EVP sees 537 shares withheld to cover RSU taxes - Stock Titan
Pablo J. Cagnoni named President at Incyte; William J. Meury remains CEO - TradingView
Incyte (NASDAQ: INCY) appoints new President and consolidates U.S. commercial - Stock Titan
UBS Lowers Price Target for Incyte (INCY) While Maintaining Neut - GuruFocus
Barclays Maintains Overweight on INCY Incyte Corporation March 2026 - Meyka
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Appoints Three to Executive Leadership Positions - Contract Pharma
UBS lowers Incyte stock price target on revenue concerns to $94 - Investing.com Australia
UBS Group Lowers Incyte (NASDAQ:INCY) Price Target to $94.00 - marketbeat.com
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):